Saturday, July 11, 2026

pharma · Peanut allergy · Allergy, Peanut

DBV Technologies

DBV Technologies is a pharma organization headquartered in CHATILLON, FR. Primary therapeutic focus areas include Peanut allergy, Allergy, Peanut. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 pate

Chatillon, FR HQ
220 Employees
EMA registrant Type
Company details
Status
Public
HQ
Chatillon, FR
Employees
220
Programs
3
Drugs
7
Patents
0
Clinical program

DBV712

Phase 3 · small molecule · Allergy, Peanut

DBV712 for Allergy, Peanut is a Phase 3 program (small_molecule) at DBV Technologies with 1 ClinicalTrials.gov record(s).

← All DBV Technologies projects Phase 3 small molecule active

Internal code V712-306 (VITESSE)

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
DBV Technologies
Phase
Phase 3
Modality
small_molecule
Indication
Allergy, Peanut
Status
active
Trials
1

Clinical trials